Position in SUPN
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$279,060
-$31,080 QoQ
Shares Held
6,000
0.0% QoQ
Ownership
0.010%
of shares outstanding
% of Portfolio
1.03%
of 13F equity value
Holder Rank
#213
of 331 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in SUPN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026PSP Research LLC holds $2,012,100 across 6 Drug Manufacturers - Specialty & Generic names. SUPN ranks #5 (13.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
3,000 | $505,620 | |
| 2 | LQDA |
Liquidia Corp
|
5,000 | $398,650 | |
| 3 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
5,000 | $319,750 | |
| 4 | ALKS |
Alkermes plc.
|
6,000 | $314,370 | |
| 5 | SUPN |
Supernus Pharmaceuticals, Inc.
This page
|
6,000 | $279,060 | |
| 6 | AMLX |
Amylyx Pharmaceuticals, Inc.
|
10,838 | $194,650 |
All Filings in SUPN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $279,060 | 6,000 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $310,140 | 6,000 | Shares | Sole | 2026-04-17 | |
| 2025-12-31 | $534,672 | 10,758 | Shares | Sole | 2026-02-06 | |
| No filing history on record for this holder in this stock. | ||||||